SciClone Pharmaceuticals

ISIN KYG4271B1023

 | 

WKN A2QP1Y

Country
China
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

SciClone Pharmaceuticals (Holdings) Ltd. is an investment holding company which manufactures and markets immune and oncology pharmaceutical products. It focuses on therapeutic areas including oncology and severe infection. The firm's marketed products include, Zadaxin. Its licensed products include Angiomax and Zometa. The company was founded on May 13, 2020 and is headquartered in Shanghai, China.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals China

Financials

Key metrics

Market capitalisation, EUR -
EPS, EUR -
P/B ratio 3.14
P/E ratio 3.22
Dividend yield 0.00%

Income statement (2023)

Revenue, EUR 411.99 m
Net income, EUR 146.47 m
Profit margin 35.55%
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.